Metastatic follicular thyroid carcinoma (FTC), unresectable or resistance to radioactive iodine, is associated with poor survival. It is believed that this kind of FTC is driven by mutated genes. However, what kind of changes of genome and underlying mechanisms are elusive. The aim of this article is to understand whether there are somatic mutations in circulating cell-free tumor DNA (cfDNA) in a FTC patient with lung and bone metastases. A 55-year-old woman was diagnosed with FTC with bone and lung metastases. Appropriate amounts of DNA were extracted from formalin-fixed, paraffin-embedded thyroid tumor, peripheral cell-free plasma, and peripheral blood leukocytes and then sequenced. The significance of DNA sequencing was evaluated. There were 13,519 common variants in both tissue DNA and cfDNA. Fifty-five somatic mutations were identified in tumor, with 5 of them nonsynonymous. Seventy-two somatic mutations were found in cfDNA, with 2 of them causing amino acid change. Sixteen common alterations existed in both samples, that is, 31.3% of all the tissue somatic mutations. This pilot study provided proof that cfDNA represents the genomic characteristics of FTC primary tissue DNA well, but also metastatic tumors. Further studies are needed to better prove the effectiveness of cfDNA in the field of thyroid cancer metastatic mechanism research and real-time monitoring.
Introduction
Most follicular thyroid carcinomas (FTCs) grow slowly after they are first identified at an early stage. It is frequently cured with adequate surgical management and radioactive iodine ablation therapy. However, few cases develop fast with lung and bone metastases. Most metastatic FTCs are unresectable and refractory to radioactive iodine and associated with poor survival. 1 Analysis of carcinogenesis has revealed that gene mutations play a very important role in the progression and development of tumors. The genetic profile of solid tumors is often obtained from surgical or biopsy specimens. However, tumor samples may not be obtained due to the confirmation of metastasis. In that situation, blood samples or biopsy can be used for analysis. Several studies of circulating cell-free DNA (cfDNA) in plasma have been used for analyzing individual loci, genes, or structural variants to quantify tumor burden and detect previously characterized resistance-conferring mutations. [2] [3] [4] Individual mutations of cfDNA and SLC5A8 and SLC26A4 hypermethylation of thyroid carcinoma including follicular carcinoma have been reported. 5 Given that sequencing of entire genes to detect FTC mutations in circulating DNA has not been demonstrated, we report a somatic mutational analysis of cfDNA in a FTC patient with lung and bone metastases by whole exome sequencing (WES).
The results demonstrate that the detection of cfDNA may reflect the mutation of FTC and further develop to be a better way for monitoring the progression of thyroid cancer.
Patient and methods

Patient
A 55-year-old woman was diagnosed with FTC with synchronous bone and lung metastases and then performed total thyroidectomy at Shanghai Jiao Tong University Affiliated Sixth People's Hospital (Figure 1 ). The informed consent for DNA sequencing was obtained from the patient. Preoperative peripheral cell-free plasma and peripheral blood leukocytes and postoperative formalinfixed, paraffin-embedded (FFPE) thyroid tumor of this patient were obtained. Procedure and protocol were reviewed and approved by the ethics committee of the Sixth People's Hospital.
DNA extraction
Three different types of DNA were obtained from this present patient, including peripheral blood leukocytes, FFPE thyroid tumor tissue, and cfDNA. Total amount of DNA were extracted according to the manufacturer's instructions using QIAamp DNA Blood Mini Kit (cat# 51106), QIAamp DNA FFPE Tissue Kit (cat# 56404), and cfDNA QIAamp circulating Nucleic Acid Kit (cat# 5514), respectively. DNA concentrations were 81 ng/ml, 85 ng/ml, and 81 ng/ml, respectively, and the optical density 260/280 is 1.86, 1.87, and 1.89, respectively. DNA samples were then subjected to Agilent 2100 for more accurate tests. All three DNA samples passed a strict quality test.
Whole exome sequencing
The three different samples above were proceeded with WES. Briefly, first, DNA libraries were established with Agilent SureSelect Human All ExonV5 kits, covering about 23,000 genes. After the quality test, qualified libraries were sequenced as 100-bp paired-end reads on Illumina HiSeq 2000 platform (Illumina, San Diego, California, USA) according to the manufacturer's instruction. All of the experiments were carried out in Zhangjiang Center for Translational Medicine, Shanghai, China. 
Data analysis
Clean data were achieved using FastQC and low quality reads were filtered. Burrows-Wheeler Alignment (0.7.12) methods were adopted to map the clean reads to reference genome (UCSC hg19). Then, Picard (http://picard.source forge.net/) and Genome Analysis Toolkit (GATK) methods were used for duplicate removal, local realignment, and base quality recalibration. GATK unified genotyper was used for variants calling.
ANNOVAR (2015-03-22) software was used to annotate variants for function (exonic, TR, intronic) reference gene, exonic function (synonymous, nonsynonymous, frameshift, stopgain, unknown), amino acid change, allele frequency (AF) 1000 Genomes Project, and dbSNP reference number.
Somatic mutations were analyzed by subtracting the variants of the peripheral blood DNA from the tumor DNA or cfDNA. T-test was used to compare the AF between different types of samples. Pearson correlation coefficient was adopted to calculate the relationship between different types of samples.
Results
Exome sequencing, sequence alignment, and variant calling
In this study, we totally sequenced three different types of DNAs from one patient. More than 10 Gb sequencing data were generated per sample. The average sequencing depth for peripheral blood DNA, tissue DNA, and cfDNA is 139Â, 140Â, and 133Â, respectively. For three samples, more than 98.7% of the exome was covered at least 10Â. The coverage rate for the above three samples was larger than 99.6%. More details are shown in Table 1 . The mutation types in different samples were nearly the same.
Variations identified in different samples
We compared variations (both SNV and Indel) in different DNA samples. Generally, a large concordance between the three types of samples was observed (Figure 2(a) ). There were 13,519 common variants in both tissue DNA and cfDNA. They shared more than 98.6% common variants compared with peripheral blood sample. The coefficient rate was 0.95 (p value < 10 À15 ) and 0.96 (p value < 10 À15 ), respectively; 1.39% of variants identified in tissue DNA were not found in peripheral blood and 1.13% of variants identified in cfDNA did not exist in peripheral blood. Comparing tissue DNA with cfDNA showed that 99.2% variants were identical (Figure 2(b) to (d) ). The Pearson coefficient between cfDNA and tissue DNA is 0.95 (Figure 2(e) ).
Somatic mutations were determined by subtracting the variants of the peripheral blood leukocytes DNA from the tumor DNA or cfDNA. Fifty-five somatic mutations were found in tissue DNA, in which 5 mutations were nonsynonymous. Seventy-two somatic mutations were found in cfDNA, in which 2 of them changed amino acid. Sixteen common alterations existed in both samples, that is, 31.3% in all the tissue somatic mutations ( Table 2) . Most of the common mutations were synonymous. In cfDNA,only GLUD2 (c.G103A: p.G35R) and HLA-B (c.A652G: p.I218 V) were nonsynonymous mutations, of which GLUD2 (c.G103A: p.G35R) was also found in the tumor DNA.
Discussion
Genome-wide sequencing of plasma DNA was first used in prenatal diagnostics, demonstrating comprehensive genome characteristics. 6 Recent studies showed that sequencing of circulating cfDNA from plasma is a potential tool for monitoring advanced cancer. Compared with traditional biopsy, cfDNA sequencing is noninvasive, easy to get samples repeatedly, and to large extent reflects the comprehensive genomic characteristic of the tumor progress. [2] [3] [4] 7 In our data, cfDNA from FTC was for the first time sequenced together with primary tumor in the advanced thyroid cancer. The results demonstrate that SNV and mutation rate of cfDNA are characterized by the features of FTC, and both tissue DNA and cfDNA shared more than 95% common alterations. It will be helpful for doctors or researchers to use cfDNA as a new method for the diagnosis and monitoring of thyroid carcinoma.
Recent studies showed that cancers arise through a process of somatic evolution that can result in substantial subclonal heterogeneity within tumors, and a large fraction of polyclonal tumors and a larger sub-clonal mutation fraction may be associated with relapse and metastasis. 8, 9 It has been established that there were different mutation variants between primary and metastatic tumors. In our results, there were different variants identified in tissue DNA and cfDNA except for common alterations. One of the reasons may be the existence of distinct mutational genes of bone and lung metastatic tumors in cfDNA. 7 In addition, the detection of genomic alteration by sequencing of cfDNA is to some extent dependent on the AF of the mutant alleles in the tissue DNA. AF value of variants which existed in both cfDNA and tissue DNA is significantly larger than that of variants only existed in tissue DNA, indicating that the higher the AF is in tissue DNA, the easier the cfDNA is to be detected. Thirdly, the sensitivity of cfDNA sequencing was dependent on sequencing depth. 10 High sequencing depth will help to find rare mutations in tissue DNA. In this study, we acquired 100 sequencing depth, so the mutation with less than 1% AF is unable to be identified theoretically.
Except for FAM69A, RAPGEF4-AS1, LOC100287072, and CDRT15L2, most of these common mutation genes are related to many functions of cancer cells, and Unc5D gene inhibits thyroid cancer cell behaviors. 11 As a common nonsynonymous mutant gene GLUD2, its activity supports cancer cell proliferation under glutamine depletion. 12 Therefore, these gene mutations may be involved in the metastatic process of FTC.
In summary, we first performed WES from cfDNA of an advanced thyroid cancer patient. This pilot study provided preliminary evidence that cfDNA represents the genomic characteristics of primary FTC, implying the risk of metastasis. Further studies guarantee sequencing of metastatic tumors, increase more cases, and determine the biomarker of cfDNA for metastasis of thyroid cancer.
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Tissue somatic mutation genes cfDNA somatic mutation genes Intersection (31%)   FAM69A  UBE2L3  TTC39A  CILP2  FAM69A  RPL5  TFAP2E  FAM69A  ZNF431  RPL5  ANKRD45  FBXO28  RPL5  DEFB124  ANKRD45  SLC9A2  RHOA  TMEM56  LOC101927631  RAPGEF4-AS1  RAPGEF4-AS1  LOC101243545  ANKRD45  UBE2L3  EOMES  ATF2  TAPT1-AS1  NUCKS1  FAM9B  TWF2  EOMES  BRD9  DIEXF  SH3KBP1  NCALD  TWF2  NEUROD6  CNRIP1  EFNB1  MPV17L  RUVBL1  TMEM229A  ERMN  PJA1  UBE2L3  TM4SF19-AS1  Unc5D  RAPGEF4-AS1  MOSPD1  Unc5D  MARCH6  DPY19L4  EOMES  MIR4424  FJX1  KCTD20  GLIPR2  TWF2  MAP6D1  SNX20  TMEM248  HRAS  GOLIM4  HLA-B  CDRT15L2  DNAJC2  FJX1  HES1  HLA-DRB1  LOC100287072  NCALD  FAM86C1  PDCL2  PPIA  EID2  HAS2-AS1  RCOR1  ANXA5  NCF1C  GLUD2  RAB1B  PDCD7  CPE  Unc5D  CXCR5  CHRNA5  NUDCD2  FAM35BP  LNX2  SNX20  CASC15  FAM35DP  CTAGE10P  ALOX15P1  EPB41L2  FJX1  EMC7  CDRT15L2  FZD1  LOC338797  SNN  LOC100287072  XPO7  SLITRK1  MPV17L  VAT1  NCALD  MIR4511  DCXR  EID2  MSANTD3-TMEFF1  IDH3A  RWDD2B  NCOA3  TMEFF1  GNPTG  GLUD2  CSGALNACT2  SNX20  AMBRA1  PAFAH1B1  NAALAD2  CDRT15L2  FGFR1OP2  LOC100287072  MICU2  CERS1  MEIS2  GDF1  MPV17L  EID2  ZNF771  GNG8  TOM1L2  ZNF816-ZNF321P  SMARCE1  GLUD2 cfDNA: cell-free DNA.
